Abstract
BNT113 is an IV administered liposomal ribonucleic acid (RNA-LPX) cancer vaccine encoding the human papillomavirus (HPV)16 oncoproteins E6 and E7. Preclinically, PD-L1 inhibition augments the anti-tumor effect of RNA-LPX-based vaccines, supporting combining BNT113 + pembrolizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
